Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2008-07-29 (17 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MARSEILLE (13010), Bouches-du-Rhone
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE GONNET : revenue, balance sheet and financial ratios
SELARL PHARMACIE GONNET is a French company
founded 17 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MARSEILLE (13010),
this company of category PME
shows in 2025 a net income positive of 79 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE GONNET (SIREN 507428043)
Indicator
2025
2024
2023
2022
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
78 828 €
-287 443 €
57 078 €
491 208 €
96 944 €
131 692 €
105 489 €
72 722 €
532 969 €
87 548 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE GONNET generates positive net income of 79 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 88 k€ -> 79 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
78 828 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 46%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 63%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
46.133%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
62.982%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2022
2023
2024
2025
Debt ratio
283.244
141.543
129.192
114.275
94.683
57.182
63.286
50.189
53.0
46.133
Financial autonomy
23.419
35.624
38.393
41.618
45.744
58.822
54.263
58.476
59.444
62.982
Repayment capacity
None
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
46.132025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good+6 pts over 3 years
In 2025, the debt ratio of SELARL PHARMACIE GONNET (46.13) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
62.98%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Good
In 2025, the financial autonomy of SELARL PHARMACIE GONNET (63.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 137.11. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2022
2023
2024
2025
Liquidity ratio
95.637
77.472
92.742
122.426
140.062
322.149
237.703
218.399
134.605
137.112
Interest coverage
None
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
137.112025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Average-31 pts over 3 years
In 2025, the liquidity ratio of SELARL PHARMACIE GONNET (137.11) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Positioning of SELARL PHARMACIE GONNET in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE GONNET is estimated at
1 252 192 €
(range 849 743€ - 1 964 861€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
849k€1252k€1964k€
1 252 192 €Range: 849 743€ - 1 964 861€
NAF 5 année 2025
Valuation method used
Net Income Multiple
78 828 €
×
15.9x
=1 252 192 €
Range: 849 744€ - 1 964 862€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE GONNET with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE GONNET
What is the revenue of SELARL PHARMACIE GONNET ?
The revenue of SELARL PHARMACIE GONNET is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMACIE GONNET profitable?
Yes, SELARL PHARMACIE GONNET generated a net profit of 79 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE GONNET ?
The headquarters of SELARL PHARMACIE GONNET is located in MARSEILLE (13010), in the department Bouches-du-Rhone.
Where to find the tax return of SELARL PHARMACIE GONNET ?
The tax return of SELARL PHARMACIE GONNET is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE GONNET operate?
SELARL PHARMACIE GONNET operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart